PDF herunterladen
Semin Neurol 2020; 40(06): 652-660
DOI: 10.1055/s-0040-1719112
Review Article

Status Epilepticus: Work-Up and Management in Adults

Assia Meziane-Tani
1   Division of Neurocritical Care, Department of Neurology, University of Cincinnati Academic Health Center, Cincinnati, Ohio
,
Brandon Foreman
1   Division of Neurocritical Care, Department of Neurology, University of Cincinnati Academic Health Center, Cincinnati, Ohio
,
Moshe A. Mizrahi
1   Division of Neurocritical Care, Department of Neurology, University of Cincinnati Academic Health Center, Cincinnati, Ohio
› Institutsangaben
› Weitere Informationen
    Lizenzen und Reprints

Abstract

Status epilepticus is one of the most common neurological emergencies and is likely to have increasing prevalence in coming years given an aging “baby boomer” population in the United States. Because status epilepticus is associated with significant morbidity and mortality, identification and treatment are paramount. Care should be taken to exclude nonorganic mimics and infectious and metabolic causes. Status epilepticus can be classified into stages with associated recommendations for escalation in therapy, increasing from push-dose benzodiazepines to continuous anesthetic infusions and other nontraditional therapies. Concurrent electroencephalogram monitoring helps to identify, localize, and assess resolution of ictal patterns alongside antiseizure drug administration. A protocol is proposed for the management of status epilepticus in a step-wise fashion.

Keywords

status epilepticus - work-up - management - adults


Publikationsverlauf

Artikel online veröffentlicht:
11. November 2020

© 2020. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Waterhouse E. Status epilepticus. Continuum (Minneap Minn) 2010; 16 (3 Epilepsy): 199-227
    PubMedGoogle Scholar
  • 2 Trinka E, Cock H, Hesdorffer D. et al. A definition and classification of status epilepticus--Report of the ILAE Task Force on Classification of Status Epilepticus. Epilepsia 2015; 56 (10) 1515-1523
    CrossrefPubMedGoogle Scholar
  • 3 Sánchez S, Rincon F. Status epilepticus: epidemiology and public health needs. J Clin Med 2016; 5 (08) 71
    CrossrefPubMedGoogle Scholar
  • 4 Chen JW, Wasterlain CG. Status epilepticus: pathophysiology and management in adults. Lancet Neurol 2006; 5 (03) 246-256
    CrossrefPubMedGoogle Scholar
  • 5 Husain AM, Sinha SR. Continuous EEG Monitoring Principles and Practice. Cham: Springer International Publishing; 2017
    CrossrefGoogle Scholar
  • 6 Dhakar MB, Hirsch LJ. Continuous EEG monitoring for status epilepticus. In: Drislane F, Kaplan PW. eds. Current Clinical Neurology: Status Epilepticus. 2nd ed. Cham: Springer; 2018: 283-298
    CrossrefGoogle Scholar
  • 7 Jirsch J, Hirsch LJ. Nonconvulsive seizures: developing a rational approach to the diagnosis and management in the critically ill population. Clin Neurophysiol 2007; 118 (08) 1660-1670
    CrossrefPubMedGoogle Scholar
  • 8 Grönheit W, Popkirov S, Wehner T, Schlegel U, Wellmer J. Practical management of epileptic seizures and status epilepticus in adult palliative care patients. Front Neurol 2018; 9: 595
    CrossrefPubMedGoogle Scholar
  • 9 Kinney MO, Craig JJ, Kaplan PW. Non-convulsive status epilepticus: mimics and chameleons. Pract Neurol 2018; 18 (04) 291-305
    CrossrefPubMedGoogle Scholar
  • 10 Huff JS, Murr N. Pseudoseizures. [Updated Feb 28, 2019]. In: StatPearls [Internet]. Treasure Island, FL: StatPearls Publishing. 2019. Jan. Available at: https://www.ncbi.nlm.nih.gov/books/NBK441871/. Accessed May 25, 2019
    Google Scholar
  • 11 Shorvon S, Ferlisi M. The treatment of super-refractory status epilepticus: a critical review of available therapies and a clinical treatment protocol. Brain 2011; 134 (Pt 10): 2802-2818
    CrossrefPubMedGoogle Scholar
  • 12 Rai S, Drislane FW. Treatment of refractory and super-refractory status epilepticus. Neurotherapeutics 2018; 15 (03) 697-712
    CrossrefPubMedGoogle Scholar
  • 13 Vasan S, Kumar A. Wernicke encephalopathy. [Updated November 14, 2018]. In: StatPearls [Internet]. Treasure Island, FL: StatPearls Publishing. 2019. Jan. Available at: https://www.ncbi.nlm.nih.gov/books/NBK470344/. Accessed May 27, 2019
    Google Scholar
  • 14 Brophy GM, Bell R, Claassen J. Neurocritical Care Society Status Epilepticus Guideline Writing Committee. et al; Guidelines for the evaluation and management of status epilepticus. Neurocrit Care 2012; 17 (01) 3-23
    CrossrefPubMedGoogle Scholar
  • 15 Trinka E, Leitinger M. Which EEG patterns in coma are nonconvulsive status epilepticus?. Epilepsy Behav 2015; 49: 203-222
    CrossrefPubMedGoogle Scholar
  • 16 Beniczky S, Hirsch LJ, Kaplan PW. et al. Unified EEG terminology and criteria for nonconvulsive status epilepticus. Epilepsia 2013; 54 (Suppl. 06) 28-29
    CrossrefPubMedGoogle Scholar
  • 17 Alldredge BK, Gelb AM, Isaacs SM. et al. A comparison of lorazepam, diazepam, and placebo for the treatment of out-of-hospital status epilepticus. N Engl J Med 2001; 345 (09) 631-637
    CrossrefPubMedGoogle Scholar
  • 18 Silbergleit R, Lowenstein D, Durkalski V, Conwit R. Neurological Emergency Treatment Trials (NETT) Investigators. RAMPART (Rapid Anticonvulsant Medication Prior to Arrival Trial): a double-blind randomized clinical trial of the efficacy of intramuscular midazolam versus intravenous lorazepam in the prehospital treatment of status epilepticus by paramedics. Epilepsia 2011; 52 (Suppl. 08) 45-47
    CrossrefPubMedGoogle Scholar
  • 19 Silbergleit R, Lowenstein D, Durkalski V, Conwit R. NETT Investigators. Lessons from the RAMPART study–and which is the best route of administration of benzodiazepines in status epilepticus. Epilepsia 2013; 54 (Suppl. 06) 74-77
    CrossrefPubMedGoogle Scholar
  • 20 Silbergleit R, Durkalski V, Lowenstein D. NETT Investigators. et al; Intramuscular versus intravenous therapy for prehospital status epilepticus. N Engl J Med 2012; 366 (07) 591-600
    CrossrefPubMedGoogle Scholar
  • 21 Lacy CF, Armstrong LL, Goldman MP, Lance LL. Drug Information Handbook. 20th ed. Hudson, OH: Lexi-Comp; 2011
    Google Scholar
  • 22 Trinka E, Höfler J, Leitinger M, Brigo F. Pharmacotherapy for status epilepticus. Drugs 2015; 75 (13) 1499-1521
    CrossrefPubMedGoogle Scholar
  • 23 Treiman DM, Meyers PD, Walton NY. Veterans Affairs Status Epilepticus Cooperative Study Group. et al; A comparison of four treatments for generalized convulsive status epilepticus. N Engl J Med 1998; 339 (12) 792-798
    CrossrefPubMedGoogle Scholar
  • 24 Litt B, Wityk RJ, Hertz SH. et al. Nonconvulsive status epilepticus in the critically ill elderly. Epilepsia 1998; 39 (11) 1194-1202
    CrossrefPubMedGoogle Scholar
  • 25 Garbovsky LA, Drumheller BC, Perrone J. Purple glove syndrome after phenytoin or fosphenytoin administration: review of reported cases and recommendations for prevention. J Med Toxicol 2015; 11 (04) 445-459
    CrossrefPubMedGoogle Scholar
  • 26 Cherian A, Thomas SV. Status epilepticus. Ann Indian Acad Neurol 2009; 12 (03) 140-153
    CrossrefPubMedGoogle Scholar
  • 27 Abou-Khalil BW. Update on antiepileptic drugs 2019. Continuum (Minneap Minn) 2019; 25 (02) 508-536
    PubMedGoogle Scholar
  • 28 Glauser T, Shinnar S, Gloss D. et al. Evidence-based guideline: treatment of convulsive status epilepticus in children and adults: Report of the Guideline Committee of the American Epilepsy Society. Epilepsy Curr 2016; 16 (01) 48-61
    CrossrefPubMedGoogle Scholar
  • 29 Valproic Acid, Drug Information, UptoDate. 2019 . Available at: https://www.uptodate.com/contents/valproate-drug-information?search=valproicacid&source=panel_search_result&selectedTitle=1∼148&usage_type=panel&kp_tab=drug_general&display_rank=1. Accessed June 5, 2019
    PubMed
  • 30 O'Connor J, Levy P, Wilson SS. Levetiracetam is as effective as phenytoin for status epilepticus with less adverse events in the ED. Crit Care Med 2015; 43 (12) 6
    PubMedGoogle Scholar
  • 31 Abou-Khalil B. Levetiracetam in the treatment of epilepsy. Neuropsychiatr Dis Treat 2008; 4 (03) 507-523
    CrossrefPubMedGoogle Scholar
  • 32 Strzelczyk A, Zöllner JP, Willems LM. et al. Lacosamide in status epilepticus: systematic review of current evidence. Epilepsia 2017; 58 (06) 933-950
    CrossrefPubMedGoogle Scholar
  • 33 Husain AM. Lacosamide in status epilepticus: update on the TRENdS study. Epilepsy Behav 2015; 49: 337-339
    CrossrefPubMedGoogle Scholar
  • 34 Phenobarbital: Drug information, UptoDate. 1996 . Available at: https://www.uptodate.com/contents/phenobarbital-drug-information?search=phenobarbital&source=panel_search_result&selectedTitle=1∼148&usage_type=panel&kp_tab=drug_general&display_rank=1. Accessed June 5, 2019
    PubMed
  • 35 Kapur J, Elm J, Chamberlain JM. NETT and PECARN Investigators. et al; Randomized trial of three anticonvulsant medications for status epilepticus. N Engl J Med 2019; 381 (22) 2103-2113
    CrossrefPubMedGoogle Scholar
  • 36 Rossetti AO, Lowenstein DH. Management of refractory status epilepticus in adults: still more questions than answers. Lancet Neurol 2011; 10 (10) 922-930
    CrossrefPubMedGoogle Scholar
  • 37 Sahinovic MM, Struys MMRF, Absalom AR. Clinical pharmacokinetics and pharmacodynamics of propofol. Clin Pharmacokinet 2018; 57 (12) 1539-1558
    CrossrefPubMedGoogle Scholar
  • 38 Kam PC, Cardone D. Propofol infusion syndrome. Anaesthesia 2007; 62 (07) 690-701
    CrossrefPubMedGoogle Scholar
  • 39 Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM. Pharmacotherapy: a pathophysiologic approach. New York, NY: Mcgraw-Hill; 2011
    Google Scholar
  • 40 Pugin D, Foreman B, De Marchis GM. et al. Is pentobarbital safe and efficacious in the treatment of super-refractory status epilepticus: a cohort study. Crit Care 2014; 18 (03) R103
    CrossrefPubMedGoogle Scholar
  • 41 Gaspard N, Foreman B, Judd LM. et al. Intravenous ketamine for the treatment of refractory status epilepticus: a retrospective multicenter study. Epilepsia 2013; 54 (08) 1498-1503
    CrossrefPubMedGoogle Scholar
  • 42 Martin BS, Kapur J. A combination of ketamine and diazepam synergistically controls refractory status epilepticus induced by cholinergic stimulation. Epilepsia 2008; 49 (02) 248-255
    CrossrefPubMedGoogle Scholar
  • 43 Niquet J, Baldwin R, Norman K, Suchomelova L, Lumley L, Wasterlain CG. Midazolam-ketamine dual therapy stops cholinergic status epilepticus and reduces Morris water maze deficits. Epilepsia 2016; 57 (09) 1406-1415
    CrossrefPubMedGoogle Scholar
  • 44 Sabharwal V, Ramsay E, Martinez R. et al. Propofol-ketamine combination therapy for effective control of super-refractory status epilepticus. Epilepsy Behav 2015; 52 (Pt A): 264-266
    CrossrefPubMedGoogle Scholar
  • 45 Zaccara G, Giannasi G, Oggioni R, Rosati E, Tramacere L, Palumbo P. convulsive status epilepticus study group of the uslcentro Toscana, Italy. Challenges in the treatment of convulsive status epilepticus. Seizure 2017; 47: 17-24
    CrossrefPubMedGoogle Scholar
  • 46 Kim DH, Kang HH, Kim M. et al. Successful use of therapeutic hypothermia for refractory nonconvulsive status epilepticus. J Epilepsy Res 2017; 7 (02) 109-114
    CrossrefPubMedGoogle Scholar
  • 47 Legriel S, Pico F, Tran-Dinh YR. et al. Neuroprotective effect of therapeutic hypothermia versus standard care alone after convulsive status epilepticus: protocol of the multicentre randomised controlled trial HYBERNATUS. Ann Intensive Care 2016; 6 (01) 54
    CrossrefPubMedGoogle Scholar
  • 48 Lancaster E. The diagnosis and treatment of autoimmune encephalitis. J Clin Neurol 2016; 12 (01) 1-13
    CrossrefPubMedGoogle Scholar